research Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage
Choosing the right tools is crucial for accurately measuring lupus activity and damage.
Search
for
Sort by
Research
210-240 / 1000+ resultsresearch Ivarmacitinib stimulates hair regrowth in severe alopecia areata
Ivarmacitinib effectively regrows hair in severe alopecia areata.
research A new self‐reported measure of disease severity of scalp hair loss in alopecia areata
The new measure helps understand the personal and emotional impact of hair loss in alopecia areata patients.
research SLAGANJE DVA INSTRUMENTA ZA OCENU KVALITETA ŽIVOTA U DERMATOLOGIJI
Using both DLQI and Skindex-16 together gives a better understanding of quality of life in skin disease patients.
research 1419 Pre-clinical in-vitro assays for high throughput screening of drug candidates for protection and restoration of immune privilege in alopecia areata
The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
research 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research Subjects with mild alopecia benefit from aminexil clinical 5: results of a large international observational study
Aminexil clinical 5 effectively reduces hair loss and is well-tolerated.
research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research The Importance of Readability: A Guide to Understanding Alopecia Areata through Multilingual Online Resources
Online articles about alopecia areata are too hard to understand and need to be clearer.
research Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study
Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
research Complete responses and SALT zero scores in alopecia areata: not the same
Significant hair regrowth doesn't always mean complete hair recovery in alopecia areata.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research An anti‐hair loss treatment in the management of mild androgenetic alopecia: results from a large, international observational study
AC5 improves hair loss and hair quality with high satisfaction rates.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients.
Baricitinib is effective and safe for treating severe alopecia areata.
research Alopecia areata - need for a revision in morphological classification and scoring
A new classification and scoring system is needed for alopecia areata to better assess severity.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
research Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes
Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.
research Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Disease severity scoring systems in dermatology
Scoring systems help doctors assess and treat skin diseases effectively.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29
Alopecia areata and androgenetic alopecia affect quality of life similarly.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research The Independent Internet Marketing Site: A Symbiotic Confederation?
The document's conclusion cannot be provided because the document is not accessible or understandable.
research A Critical Evaluation of Evaluations for Long-form Question Answering
Current automatic metrics for long-form question answering don't align with human preferences; a multi-faceted evaluation approach is needed.
research Patient-reported outcome assessment and objective evaluation of chemotherapy-induced alopecia
The Hair Check tool can measure hair loss, but patients' own reports are more reliable for assessing hair loss during chemotherapy.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research ISHRS Best Practices Survey Project MODULE: Anesthesia and Emergency SUMMARY ANALYSIS
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.